Commit To Buy Zymeworks At $12.50, Earn 88.5% Annualized Using Options

An analysis highlights the potential for an 88.5% annualized return from selling a January 2026 put option on Zymeworks Inc (ZYME) with a $12.50 strike price. This strategy is profitable unless ZYME shares decline by over 34.2% from their current $19.13, which would result in a potential cost basis of $10.50 if exercised. The assessment considers ZYME's 51% trailing twelve-month volatility, suggesting a favorable risk-reward profile for this options play.

Analysis

Selling a January 2026 put option on Zymeworks Inc (ZYME) at a $12.50 strike price offers an 88.5% annualized rate of return from premium collection. This strategy is profitable as long as ZYME shares do not decline significantly, providing income to the put seller.

The primary risk involves ZYME's stock price falling below the strike, specifically a decline exceeding 34.2% from its current $19.13 market price. If exercised, the investor would acquire shares at an effective cost basis of $10.50 per share, excluding broker commissions.

ZYME's trailing twelve-month volatility stands at 51%, a factor considered alongside fundamental analysis to assess the risk-reward profile of this put sale. The strategy's upside is limited to the premium collected, unlike direct share ownership which captures full upside potential.

Key Decisions for Investors

• Investors should weigh the attractive 88.5% annualized premium yield against the potential obligation to purchase ZYME shares at an effective $10.50 cost basis if the stock drops over 34.2% by January 2026.
• Evaluate ZYME's fundamental outlook and the implications of its 51% historical volatility when assessing the probability of the $12.50 strike being breached.
• Recognize that this put-selling strategy limits upside to the premium collected, contrasting with direct equity ownership which captures full share price appreciation.